Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study

Abstract

Background:

The aim of this study was to prospectively analyse, for the first time worldwide by in vivo clinical confocal microscopy (CCM), corneal side effects secondary to the use of epidermal growth factor receptor (EGFR) inhibitor depatuxizumab mafodotin (ABT-414) in a cohort of patients affected by EGFR-amplified recurrent glioblastoma.

Methods:

Each enrolled patient underwent full ophthalmologic examination including in vivo CCM of the cornea. Each patient was examined at baseline and every 2 weeks during treatment as long as patient conditions allowed it.

Results:

A total of 10 patients were consecutively enrolled. Median follow-up was 5 months. No Common Terminology Criteria for Adverse Events Version 4.0 grade 4 toxicity was documented. Two (20%) grade 3 toxicities were documented at week 8. CCM examination detected in all eyes multiple and diffuse hyperreflective white round spots in the corneal basal epithelial layers (100%), progressive subbasal nerve plexus layer fibres fragmentation followed by full disappearance (100%) and appearance of round cystic structures in the corneal epithelium (100%). All CCM documented side effects reached the peak of prevalence and severity after a median of 3 infusions. After treatment discontinuation, the reversibility of corneal side effects was documented at CCM after a median of 4 weeks.

Conclusion:

ABT-414 toxicity is not only directed to the corneal epithelium, but also to corneal nerves. Side effects are detectable in all treated patients and CCM documents early corneal epithelium and subbasal nerve plexus toxicity, with subsequent progressive restoration after treatment discontinuation. Ocular side effects due to ABT-414 can be manageable.

Keywords

ABT-414 confocal microscopy cornea depatuxizumab mafodotin EGFR-inhibitor epithelium glioblastoma head and neck cancer side effects subbasal nerve plexus

Introduction

Epidermal growth factor receptor (EGFR) is commonly over expressed, amplified or mutated in many human cancer cells.¹ Therefore, EGFR-inhibitors have been introduced for the treatment of different solid tumors.^1,2 Monoclonal antibodies against EGFR have been proven to improve progression-free survival and overall survival of patients affected by tumours with EGFR overexpression, while preserving a reasonable quality of life for the patient.² Antibody-drug conjugates (ADC) are a promising class of anticancer drugs characterized by the targeting properties of monoclonal antibodies and the antitumour effects of cytotoxic agents. Depatuxizumab mafodotin (formerly ABT-414) is an ADC consisting in a monoclonal antibody (depatuxizumab) binding a specific epitope of the EGFR and a chemotherapeutic agent, monomethyl-auristatin-F, a strong antimitotic agent that inhibits cell division by blocking the polymerization of tubulin.^3,4

Glioblastoma is the most common primary central nervous system malignant tumour in adults, with a 5-year survival rate around 5%.^1,5,6 Frequent abnormalities have been observed in the expression of the EGFR in glioblastoma, and approximately 50% of glioblastomas harbour EGFR gene amplification, with consequent overexpression of the EGFR protein.^1,7 Therefore, ABT-414 is considered a promising drug for patients affected by this tumor.¹ In the eye, EGFR is constitutively localized in the basal epithelial cells of the cornea and conjunctiva and corneal toxicity has been previously reported in patients treated by monoclonal antibodies against EGFR.^1,8–13 Unfortunately, the analysis of ocular side effects secondary to ABT-414 was performed using only standard ophthalmological procedures, mainly slit lamp examination with fluorescein corneal staining. Therefore, morphological analysis, at microscopic level, of corneal and ocular surface side effects related to the use of ABT-414 was never performed in vivo.

The aim of this study was to prospectively analyse, for the first time worldwide, corneal side effects by clinical confocal microscopy (CCM) in a cohort of patients affected by glioblastoma and treated with the EGFR-inhibitor ABT-414 as compassionate use in combination with temozolomide.

Materials and methods

This was an institutional, observational, descriptive cohort study with prospective enrolment, compliant with the tenets of the Declaration of Helsinki and approved by the Veneto Institute of Oncology IOV-IRCCS institutional review board (No. 08.2019). Patients treated with ABT-414 plus temozolomide for EGFR-amplified, recurrent glioblastoma, were consecutively recruited. Informed consent covering patient inclusion in the present study was obtained from each patient. Treatment with ABT-414 (1.5 mg/kg every 2 weeks) plus temozolomide 150–200 mg/m²/day for five consecutive days every 28 days was continued until either intolerable toxicity or disease progression was reached, as assessed using the response assessment in neuro-oncology criteria.^1,14 Brain magnetic resonance imaging was performed at baseline, every 2 months or when clinically indicated. Patients were treated at Veneto Institute of Oncology (Padua, Italy) and started the treatment from November 2018 to April 2019, as compassionate use. Each enrolled patient underwent full ophthalmologic examination, including best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol, and slit lamp examination with fluorescein corneal staining.¹⁵ Visual acuity reduction of at least five letters was defined as clinically significant. In vivo CCM of the cornea was also performed at baseline and during follow-up. During the treatment, the appearance of conjunctival hyperaemia, intraepithelial cysts, stromal oedema, superficial punctate epitheliopathy and blepharitis was recorded. The presence of ocular symptoms (blurred vision, eye pain, photophobia) and signs (conjunctivitis, corneal ulcer and keratitis) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The superficial punctate epitheliopathy was also graded using the Oxford grading scheme to describe corneal epithelial damage.¹⁶ CCM was performed using Heidelberg Retina Tomography with the Rostock Cornea Module (HRTIII/RCM, Heidelberg Engineering, Germany). The HRTIII employs a 670 nm wavelength diode laser source and provides cross-sectional images of 400 × 400 µm, with a lateral resolution of 1 µm. For CCM imaging, a disposable sterile polymethylmethacrylate cap (TomoCap; Heidelberg Engineering) filled with hydroxypropyl methylcellulose 2.5% (GenTeal gel; Novartis Ophthalmics, East Hanover, New Jersey, USA) was placed on the objective lens of the Cornea Module. After instillation of topical anaesthesia, a drop of hydroxypropyl methylcellulose gel was added to the TomoCap to improve optical coupling. The Corneal Module was advanced manually until obtaining an appropriate cap contact with the corneal surface. Using the sequence mode of the CCM, which acquires 100 images per sequence, images were obtained layer by layer for the full cornea thickness. For each patient, 1–3 sequence scans were recorded with a rate of 3 frames per second. The presence of multiple and diffuse epithelial hyperreflective white round spots and the presence of round cystic structures in the corneal epithelium were separately graded as mild (⩽5 in a single CCM image) moderate (5–10 in a single CCM image) and severe (⩾10). Keratocytes activation was defined as the presence of more than 25% activated keratocytes (keratocytes with visible cytoplasmic processes) at a depth of 100 μm.¹⁷ Each patient was examined at baseline (before first drug infusion), and every 2 weeks. Follow-up was planned over a 6-month period from starting treatment and performed until patients’ conditions allowed the examination.

Results

Population, treatment and baseline ophthalmologic characteristics

A total of 10 patients affected by EGFR-amplified, recurrent glioblastoma and treated with ABT-414 were consecutively recruited. Patient characteristics are reported in Table 1.

Table 1.

Clinical and demographic characteristics of enrolled patients.

Baseline characteristics
Number of patients (eyes)	10 (20)
Average age at inclusion, years, mean ± SD	59 ± 12
Gender (Male/Female)	0.60
Karnofsky performance status, baseline
100	4 (40%)
90	3 (30%)
80	2 (20%)
70	1 (10%)
Median number of ABT-414 infusion (range)	4 (2–6)
Median follow up time	5 months (95% CI 3.2–6.7)
Median treatment time	2 months (95% CI 1.5–2.5)

ABT-414, depatuxizumab mafodotin; CI, confidence interval; SD, standard deviation.

At the time of our analysis, median follow up time was 5 months [95% confidence interval (CI) 3.2–6.7]. The median treatment time was 2 months (95% CI 1.5–2.5). The median number of ABT-414 infusion was 4 (range 2–6). No patient discontinued the treatment because of ocular side effects. Two patients (20%) reduced ABT dose to 1 mg/kg due to grade 3 ocular side effects. In total, six patients (60%) were still in treatment 2 months after starting the therapy. Six patients were followed at least 1 month after treatment discontinuation and three patients up to 2 months. The mean BCVA at baseline was 86 ± 3 letters. No significant corneal or anterior segment clinically relevant abnormalities were documented at baseline (by biomicroscopy and CCM), excluding cortical cataract in two patients (3 eyes) (Table 2).

Table 2.

Clinical and clinical laser scanning in vivo confocal microscopy characteristics during treatment and follow up.

Patients characteristics, N (percentage) (grade)	Baseline	15 days	1 month	2 months
Patients in follow-up	10 (100%)	10 (100%)	10 (100%)	10 (100%)
Patients in treatment	0 (0%)	10 (100%)	10 (100%)	6 (60%)
Blurred vision	0 (0%) (NA)	8 (80%) (grade 1; grade 2)	10 (100%) (grade 2; grade 2)	10 (100%) (grade 2; grade 2)
Eye pain	0 (0%) (NA)	9 (90%) (grade 1; grade 2)	10 (100%) (grade 2; grade 2)	10 (100%) (grade 2; grade 2)
Photophobia	0 (0%) (NA)	5 (50%) (grade 1; grade 2)	10 (100%) (grade 2; grade 2)	10 (100%) (grade 2; grade 2)
Conjunctivitis	0 (0%) (NA)	10 (50%) (grade 1; grade 2)	14 (70%) (grade 2; grade 2)	14 (70%) (grade 2; grade 2)
Corneal ulcer	0 (0%) (NA)	0 (0%) (NA)	0 (0%) (NA)	2 (10%) (grade 2; grade3)
Keratitis	0 (0%) (NA)	10 (50%) (grade 2; grade2)	20 (100%) (grade 2; grade 2)	20 (100%) (grade 2; grade 3)
Biomicroscopy
Conjunctival hyperaemia	0 (0%)	10 (50%)	14 (70%)	14 (70%)
Blepharitis	0 (0%)	12 (60%)	14 (70%)	14 (70%)
Superficial punctate epitheliopathy	0 (0%)	8 (40%)	16 (80%)	20 (100%)
Intraepithelial cysts	0 (0%)	10 (50%)	20 (100%)	20 (100%)
Corneal stroma oedema	0 (0%)	0 (0%)	2 (10)	9 (45%)
Clinical laser scanning in vivo confocal microscopy
Basal epithelial hyperreflective white round spots	0 (0%)	20 (100%)	20 (100%)	20 (100%)
Round cystic structure characterized by an hyperreflective wall	0 (0%)	12 (70%)	20 (100%)	20 (100%)
Fragmentation and reduction of subbasal nerve plexus fibres	NA	20 (100%)	20 (100%)	20 (100%)
Subbasal nerve plexus disappearance	0 (0%)	0 (0%)	14 (70%)	20 (100%)
Stromal keratocytes activation	0 (0%)	0 (0%)	2 (10)	9 (45%)
ETDRS score, mean ± SD (range)	86 ± 3 (79–88)	84 ± 4 (76–86)	68 ± 9 (55–76)	64 ± 11 (52–72)

ETDRS, Early Treatment Diabetic Retinopathy Study; NA, not applicable; N, number; SD, standard deviation.

Corneal and ocular surface side effects

The prevalence and severity (median and maximal severity) of ocular side effects in our cohort of patients is reported in Table 2. No CTCAE grade 4 toxicities were documented. Two grade 3 toxicities (20%) were documented at week 8. Symptoms were experienced by all patients starting at 10 ± 3 days after the first drug infusion and included: blurred vision (eight patients), eye pain (nine patients) and photophobia (five patients) (Table 2). At the first follow-up examination, the mean BCVA was 84 ± 4 letters and no patient experienced more than five ETDRS letter losses from baseline. Slit lamp examination with fluorescein corneal staining examination documented the appearance of mild conjunctival hyperaemia (10 eyes), mild blepharitis (12 eyes), superficial punctate epitheliopathy (8 eyes) (Figure 1) and multiple corneal epithelial cysts (10 eyes) (Figure 2). When present, superficial punctate epitheliopathy was graded as moderate in four cases and severe in another four cases. The corneal epithelial cysts were characterized by round shape and optically empty content, with preferential distribution in the central cornea (Figure 2). CCM examination revealed the presence of multiple and diffuse epithelial hyperreflective white round spots in all examined eyes, mainly distributed in the basal epithelial layers (Figure 3). The presence of these spots was graded as mild in 8 eyes, moderate in 10 eyes and severe in 2 eyes. The subbasal nerve plexus layer was characterized by evident fibre fragmentations and a reduction in the number of fibres in all eyes, mainly when compared with baseline images (Figure 4). The documentation of the round epithelial cystic structures, characterized by a hyperreflective and well-defined wall, was documented in 12 eyes and graded as mild in 9 and moderate in 3 eyes. An increase in ocular symptoms and signs was documented in the first 2 months, with a subsequent stabilization over time during the treatment period (Table 2). The superficial punctate epitheliopathy increased in incidence, affecting 16 eyes at 4 weeks and 20 eyes at 8 weeks, and became severe in 6 eyes at 4 weeks and in 12 eyes at 6 weeks. A single eye presented two severe episodes of corneal abrasion-like epithelial defect (corneal ulceration) with positive fluorescein staining associated with mild anterior chamber inflammation. This side effect regressed using topical antibiotics and steroids. Corneal stroma oedema was documented in two eyes at a 4-week examination and its incidence increased at 4 weeks (nine eyes). Clinically significant BCVA reduction started at 4 weeks (68 ± 9 ETDRS score), with stabilization at 8 weeks (64 ± 11 ETDRS score). By CCM, the evidence of multiple and diffuse epithelial hyperreflective white round spots, documented in all patients since week 2, persisted during the treatment and increased in severity, becoming severe in 7 eyes at 4 weeks and in 11 eyes at 6 weeks. Conversely, the presence of the round cystic structures at CCM were documented in all patients at week 4, persisting during the treatment (Table 2). Round cystic structures also increased in severity, becoming severe in five eyes at 4 weeks and in nine eyes at 6 weeks. The subbasal nerve plexus layer, characterized by fibre fragmentation and reduction at week 2, was then characterized by a complete disappearance of the plexus fibres in 14 eyes (70%) at week 4 and in 20 eyes (100%) at week 8. Keratocytes activation in the corneal stroma was also documented in two eyes at a 4-week examination and its incidence increased at 4 weeks (nine eyes). All documented side effects reached the peak of prevalence and severity in a range of 4–8 weeks (2–4 ABT 414 infusions; median 3 infusions) from starting the treatment, maintaining the same prevalence and severity during the subsequent treatment period.

Figure 1.

Standard slit lamp examination with fluorescein staining in a patient affected by superficial punctate epitheliopathy secondary to ABT-414 systemic treatment.

Figure 2.

Standard slit lamp examination in a patient showing the presence of diffuse intraepithelial cysts secondary to ABT-414 systemic treatment. Please note the round shape and an optically empty content.

Figure 3.

Clinical in vivo confocal microscopy examination of a patient treated with ABT-414. At baseline, basal epithelial layers appear normal (a). Two weeks after the first drug infusion (b), the basal epithelium is characterized by a diffuse and mild increase of cells reflectivity, and by the appearance of some epithelial hyperreflective white round spots. At 8 weeks follow-up (c), the basal epithelium is characterized by a diffuse background of increased reflectivity, by an increased number of the hyperreflective white round spots and by the appearance of round cystic structures, characterized by an hyperreflective and well-defined wall. Eight weeks after treatment discontinuation (d), basal epithelial layers are characterized by an advanced restoration of its structure.

Figure 4.

Clinical in vivo confocal microscopy examination of a patient treated with ABT-414. At baseline, subbasal nerve plexus layer appears normal (a). At 2 weeks follow-up (b), the subbasal nerve plexus layer is characterized by an initial fragmentation, followed by a subtotal disappearance of the nerve fibres at 4 weeks follow-up (c). Eight weeks after treatment discontinuation (d), the subbasal nerve plexus is characterized by an advanced restoration of its structure.

Effect of treatment discontinuation

In the three patients followed for at least 2 months after treatment discontinuation, corneal side effects regressed progressively. After 8 weeks post treatment discontinuation, corneal side effects were almost completely resolved, with partial subbasal nerve plexus restoration and the disappearance of most epithelial cysts (Figures 3 and 4). Punctate keratopathy also became mild, progressively reducing in severity. All these patients reached the baseline ETDRS score. In six patients, followed for at least 1 month after treatment discontinuation, there was an evident trend toward reversibility of ocular side effects.

Discussion

Epidermal grow factor (EGF) is a small polypeptide characterized by a potent stimulatory effect on epidermal cell proliferation and differentiation.⁸ It plays a key role in the maintenance of ocular surface homeostasis.⁸ In physiological situations, EGF binds the EGFR, which is localized in the basal cell layer of the conjunctiva and cornea, mainly in peripheral and limbal epithelial corneal cells.^8,18 ABT-414 is a promising new drug, and a recent randomized comparative phase II trial (INTELLANCE 2) showed that ABT-414, in combination with temozolomide, could improve survival in recurrent glioblastoma patients compared with the standard treatment (temozolomide alone or lomustine).¹⁹ This drug binds an epitope present only when EGFR is in an extended (activated) conformation.^1,7,10,11 Therefore, it seems to be associated with less systemic adverse events, avoiding toxicity typically associated with other systemic EGFR drugs inhibitors.¹ Other authors have reported ocular adverse events during systemic therapy with EGFR inhibitors. Ahn and colleagues reported corneal toxicity secondary to systemic vandetanib, an inhibitor of both EGFR and VEGFR2, clinically describing using the standard slit lamp examination with fluorescein corneal staining, the development of vortex keratopathy and diffuse subepithelial haze in both corneas of one treated patient.¹³ In addition, Tullo and colleagues, using the same standard approach, reported the development of mild conjunctival hyperaemia associated with mild and reversible superficial punctate keratopathy, blepharitis, trichiasis, keratoconjunctivitis sicca and meibomitis during treatment with Gefitinib, an EGFR tyrosine kinase inhibitor.¹² Other authors reported ocular toxicity specifically due to ABT-414, mainly analysing ocular side effects from a medical oncologist’s point of view, reporting the common appearance of dry eyes, blurred vision, eye pain and photophobia, secondary to microcystic corneal degeneration.^1,9
–11 These authors reported that most patients experienced at least one ocular adverse effect, including blurred vision (65%) and dry eye (29%).¹ A recent study analysed the safety and efficacy of ABT + temozolomide in 60 recurrent glioblastoma patients with EGFR amplified; the authors showed that 87% of patients reported any grade of ocular adverse events. Similarly to our results, 22% of cases reported severe (grade 3–4) adverse events. Among these, the most frequent severe adverse events were keratitis (22%), blurred vision (5%) and photophobia (3%). Unfortunately, these side effects were not fully characterized, and just one case report (one patient) was described by the standard ophthalmological point of view.¹⁹

Confocal microscopy was introduced in the ophthalmological clinical practice as a noninvasive tool to observe at high magnification the structure of the human cornea and conjunctiva in vivo. The present study is the first study, to our knowledge, to support clinical findings obtained by standard ophthalmological diagnostic procedures (slit lamp examination with fluorescein corneal staining) with CCM. The use of this noninvasive imaging and diagnostic tool enables morphological and quantitative analysis of the ocular surface microstructure, allowing a high magnification imaging of different corneal structures in vivo, including corneal nerves. Using CCM, we have described the early appearance by CCM of multiple and diffuse epithelial hyperreflective white round spots. The presence of these spots is the first clinical detectable side effect to the corneal epithelium, probably representing the early phase of basal epithelial cells death secondary to ABT-414 toxicity. Conversely, the round cystic structures, which became visible only later, may be the evolution of these degenerated cells transforming into epithelial degenerative cysts.

Our data shows, for the first time, that corneal damage by ABT-414 is not limited to the corneal epithelium, but also affects the corneal nerves and anterior corneal stroma. We hypothesize that the corneal subbasal nerve plexus involvement is explained by its location immediately under the basal epithelial membrane. Indeed, in physiological conditions EGFR is constitutively localized in the corneal basal epithelial cells, and ABT-414 binding to it could deliver its direct cytotoxic effect into the corneal basal epithelial layer, in the subbasal nerve plexus and also in the anterior stroma.⁸ Moreover, an ADC could hypothetically contribute to ocular toxicity not only through an on-target mechanism (antibody-mediated homing and delivery), but also by an off-target mechanism (uptake of the unconjugated cytotoxin by tissue having a specific tropism for it). Therefore, a second pathogenetic hypothesis is the possible existence of a direct uptake of ABT-414 into rapid proliferating cells of the corneal limbus (corneal stem cells) that differentiate and give rise to the corneal epithelium, moving from the limbus toward the central cornea.^20
–22 This migration may also explain the preferential location of the epithelial cysts in the central cornea. Eaton and colleagues suggest that this intracellular uptake can be simply related to the general mechanisms of endocytosis in cells characterized by high replication and differentiation rate, rather than specific targeting of ABT-414 to activated EGFR in the cornea.²¹ Although this mechanism is suggested by preclinical observations reporting that corneal side effects are present regardless of the antibody epitope of the ADC, this second hypothesis may also suggest that human stem cells, in tissues characterized by high replication and differentiation rate, may be affected by similar toxicity.²¹ Conversely, nonocular side effects are less common and severe,²² suggesting that corneal homing may be present. The most frequently reported nonocular side effect is fatigue sensation (41%).²² Considering that our CCM analysis demonstrated that corneal innervation is directly affected by the ABT-414 toxicity, we cannot exclude a similar mechanism of toxicity at the level of the neuromuscular junctions or other peripheral nervous structures responsible for this side effect.

A third pathogenetic hypothesis of corneal ABT-414 toxicity is that the antibody-drug conjugate may be taken up from the blood flow by the lacrimal gland and secreted with tears, delivering the drug to the cornea.^20
–22

Our study confirms that ocular side effects can improve upon treatment discontinuation. However, a precise definition of a median time to resolution was not established because of the limited number of patients followed after treatment discontinuation. This limitation of the study is related to the patient’s systemic conditions: most of our patients discontinued follow-up for progressive disease. A second limitation of this study is the relative low number of patients enrolled. However, this is the first study on ABT-414 ocular toxicity analysed in vivo by CCM, obtaining a detailed morphological and quantitative analysis of the ocular surface microstructure. The third limitation of this study is that temozolomide may also have some ocular toxicity in addition to ABT-414. Nevertheless, ocular side effects of temozolomide are extremely rare, and not typically directed to the cornea.²³

In conclusion, this is the first study analysing ocular side effects by CCM in patients with recurrent glioblastoma treated with ABT-414. ABT-414 toxicity is not only directed to the corneal epithelium, but also to the subbasal nerve plexus. Corneal side effects are detectable in all treated patients, and all documented side effects reached the peak of prevalence and severity after a range of 1–2 months (2–4 ABT-414 infusions; median 3 infusion) from starting the treatment, maintaining the same prevalence and severity during the subsequent treatment period. After treatment discontinuation there is a significant evident trend toward reversibility, and CCM documented a progressive corneal epithelium and subbasal nerve plexus regeneration. The added value of using CCM when quantifying corneal side effects of affected patients is proven by our data. However, these data, obtained in vivo in a fully noninvasive way, demonstrated that ABT 4-14 can be safe and its ocular side effects can be manageable.

Footnotes

Acknowledgements

RP, GL, LF and EM contributed to the study conceptualization, design, interpretation of data, drafting and revising and agreed on the final approval and to be accountable for all aspects of the work.

FL, DL, MP, MC, GM, SB and VZ contributed to data acquisition/analysis/interpretation, drafting and revising of work, formal analysis, final approval and agree to be accountable for all aspects of the work.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The contribution of the Fondazione Bietti in this paper was supported by the Ministry of Health and Fondazione Roma.

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

van den Bent

Gan

Lassman

, et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol 2017; 80: 1209–1217.

Liang

Fang

, et al. Network meta- analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 2014; 9: e85245.

Reilly

Phillips

Buchanan

, et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther 2015; 14: 1141–1451.

Phillips

Boghaert

Vaidya

, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther 2016; 15: 661–669.

Stupp

Hegi

Mason

, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.

Ostrom

Gittleman

Liao

, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014; 16(Suppl. 4): iv1–iv63.

Padfield

Ellis

Kurian

KM.

Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol 2015; 5: 5.

Nakamura

Sotozono

Kinoshita

The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 2001; 72: 511–517.

Eaton

Miller

Mannis

, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015; 31: 589–604.

10.

Reardon

Lassman

van den Bent

, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol 2017; 19: 965–975.

11.

Gan

Reardon

Lassman

, et al. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapyor in combination with temozolomide in patients with glioblastoma. Neuro Oncol 2018; 20: 838–847.

12.

Tullo

Esmaeli

Murray

, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in phase I and II clinical trials. Eye (Lond) 2005; 19: 729–738.

13.

Ahn

Wee

Lee

, et al. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 2011; 25: 355–357.

14.

Ellingson

Wen

Cloughesy

TF.

Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 2017; 14: 307–320.

15.

National Eye Institute, Early Treatment Diabetic Retinopathy Study Research Group. Early treatment diabetic retinopathy study (ETDRS). Manual of operations. Springfield, VA: U.S. Department of Commerce, National Technical Information Service, 1985.

16.

Bron

AJ.

Diagnosis of dry eye. Surv Ophthalmol 2001; 45: S221–S226.

17.

Shtein

Kelley

Musch

, et al. In vivo confocal microscopic evaluation of corneal wound healing after femtosecond laser-assisted keratoplasty. Ophthalmic Surg Lasers Imaging 2012; 43: 205–213.

18.

McClintock

Ceresa

BP.

Transforming growth factor-{alpha} enhances corneal epithelial cell migration by promoting EGFR recycling. Invest Ophthalmol Vis Sci 2010; 51: 3455–3461.

19.

Lassman

van den Bent

Gan

, et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol 2019; 21: 106–114.

20.

Eshraghi

Mantopoulos

Suh

, et al. Corneal toxicity induced by ABT-414 therapy for glioblastoma multiforme: a case report. Case Rep Ophthalmol 2018; 9: 479–483.

21.

Eaton

Miller

Mannis

, et al. Ocular adverse events associated with antibody drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015; 31: 589–604.

22.

Goss

Vokes

Gordon

, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer 2018; 124: 2174–2183.

23.

Stupp

Taillibert

Kanner

, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomidealone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306–2316.